Recombinant Human Apolipoprotein CIII protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg3387
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human Apolipoprotein CIII protein Ser21-Ala99 (Accession# P02656) with a rabbit IgG Fc tag at the N-terminus. |
| GeneID | 345 |
| Accession | P02656 |
| PredictedSize | 35.6 kDa |
| SDS-PAGE | 34-40 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Apolipoprotein CIII is a small secreted protein encoded by the APOC3 gene, primarily synthesized and secreted into the plasma by the liver. It is a component of lipoprotein particles such as high-density lipoprotein and very-low-density lipoprotein. Its main physiological function is to regulate lipid metabolism by inhibiting the activity of lipoprotein lipase and interfering with hepatic uptake of triglyceride-rich lipoproteins, thereby delaying the clearance of plasma triglycerides. Research indicates that elevated APOCIII levels are an independent risk factor for severe hypertriglyceridemia, insulin resistance, and atherosclerosis, and are closely associated with cardiovascular events. Consequently, APOCIII has become a critical therapeutic target for managing metabolic syndrome and cardiovascular diseases, with targeted drugs such as the antisense oligonucleotide Volanesorsen already in clinical use.
References:
1. Christopoulou, Eliza et al. Diabetes/metabolism research and reviews vol. 35,3 (2019): e3118. 2. Valladolid-Acebes, Ismael et al. International journal of molecular sciences vol. 22,2 (2021): 932. 3. Naber, Annemieke et al. International journal of molecular sciences vol. 24,19 (2023): 14844. 4. Gouni-Berthold, Ioanna. Atherosclerosis. Supplements vol. 30 (2017): 19-27.